{"ticker": {"uuid": "395e904b-a8e7-4795-b37b-55f3445d832b", "symbol": "MDGL", "name": "Madrigal Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Dow, S&P 500, Nasdaq Futures Rise After Trump\u2019s 10-Day Iran Pause: Why META, DJT, U, KOD, MDGL Are Trending After-Hours", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOZFFaTFpONXJlMV9wR2hQSU5mRTU3S3FQWjYwVmxSNFppcFpmQ0djM2JrQ1RzY09BTEl6MllqS2dFVGdoX2xvSkt4SWZieVFNLUtiVXJxN1ByeFVWRlJVZ2FZaU01S0UzNmdpTXMyejM3MGxZeDFTRnNqRlVYVjBFVVUxVWJqZTJOVF9SWFJWU0ctWGZzY0Fvb3ZTT2trWWxhcFJkUnpQb1hoVEFtMnd2RW1mVUNtbFJZTmZWNGZCcVIxWjdtUUE?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-19T10:24:50+00:00", "published_display": "19 Jul 2026 10:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citizens JMP Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Cuts Target Price to $739", "summary": "Citizens JMP has reiterated its Buy rating on Madrigal Pharmaceuticals (MDGL.US) but has reduced its target price to $739. The adjustment in the target price suggests a revised outlook on the company's valuation while maintaining a positive sentiment on its stock performance pote", "url": "https://www.moomoo.com/news/post/73137328/citizens-jmp-maintains-madrigal-pharmaceuticals-mdglus-with-buy-rating-cuts", "source_name": "Moomoo", "published_at": "2026-07-17T20:40:57", "published_display": "17 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026", "summary": "Madrigal Pharmaceuticals announced it will release its second-quarter 2026 financial results on July 30, 2026, before the U.S. financial markets open. Following the release, the company will host a live webcast at 8 a.m. Eastern Time to discuss its financial and operating results", "url": "https://www.globenewswire.com/news-release/2026/07/16/3328398/0/en/madrigal-pharmaceuticals-to-release-second-quarter-2026-financial-results-and-host-webcast-on-july-30-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-17T08:40:14", "published_display": "17 Jul 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Madrigal Pharmaceuticals (MDGL) Fully Valued Ahead Of Its July 30 Earnings?", "summary": "Madrigal Pharmaceuticals (MDGL) is approaching its Q2 2026 earnings release on July 30, with a current market value of US$12.7 billion. Despite recent share price momentum and a 5-year return of roughly 6x, the company is still considered 19.6% undervalued, with a fair value esti", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/is-madrigal-pharmaceuticals-mdgl-fully-valued-ahead-of-its-j/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-17T04:11:56", "published_display": "17 Jul 2026 04:11", "sentiment": "positive", "sentiment_pct": 68, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Madrigal management to discuss Q2 results at 8 a.m. Eastern July 30", "summary": "Madrigal Pharmaceuticals (Nasdaq: MDGL) announced it will release its second-quarter 2026 financial results on Thursday, July 30, 2026, before U.S. markets open. Management will host a live webcast at 8:00 a.m. Eastern time to review the results, with a replay available approxima", "url": "https://www.stocktitan.net/news/MDGL/madrigal-pharmaceuticals-to-release-second-quarter-2026-financial-xuxzpv0t0mcs.html", "source_name": "Stock Titan", "published_at": "2026-07-16T12:10:41", "published_display": "16 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biogen (BIIB) and Cadrenal Therapeutics, Inc. (CVKD)", "summary": "This article highlights bullish analyst ratings for three healthcare companies: Madrigal Pharmaceuticals (MDGL), Biogen (BIIB), and Cadrenal Therapeutics, Inc. (CVKD). Analysts from Truist Financial, Goldman Sachs, and Noble Financial reiterated Buy ratings, providing price targe", "url": "https://www.theglobeandmail.com/investing/markets/stocks/BIIB/pressreleases/3296321/analysts-offer-insights-on-healthcare-companies-madrigal-pharmaceuticals-mdgl-biogen-biib-and-cadrenal-therapeutics-inc-cvkd/", "source_name": "The Globe and Mail", "published_at": "2026-07-15T12:41:49", "published_display": "15 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal Pharmaceuticals' Three New Patents Support Patent Extension Into 2045, Truist Says", "summary": "Truist Securities has reiterated its Buy rating on Madrigal Pharmaceuticals (MDGL) after the company secured three new patents for its drug resmetirom. These patents are expected to extend the drug's exclusivity until 2045, enhancing its market position and providing long-term va", "url": "https://www.moomoo.com/news/post/72876322/madrigal-pharmaceuticals-three-new-patents-support-patent-extension-into-2045?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T22:42:19", "published_display": "13 Jul 2026 22:42", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal receives three new U.S. patents for resmetirom drug", "summary": "Madrigal Pharmaceuticals Inc. has been granted three new U.S. patents for its drug resmetirom, marketed as Rezdiffra, which treats metabolic dysfunction-associated steatohepatitis (MASH). These patents cover treatment for F2/F3 fibrosis stages and well-compensated cirrhosis, exte", "url": "https://www.investing.com/news/company-news/madrigal-receives-three-new-us-patents-for-resmetirom-drug-93CH-4788415", "source_name": "Investing.com", "published_at": "2026-07-13T15:12:15", "published_display": "13 Jul 2026 15:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal Pharmaceuticals Expands Rezdiffra Patent Protection With Three New Patents", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/madrigal-pharmaceuticals-expands-rezdiffra-patent-123800208.html", "source_name": "MT Newswires", "published_at": "2026-07-13T12:38:00+00:00", "published_display": "13 Jul 2026 12:38", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Madrigal Pharmaceuticals (MDGL) Secures New Patents to Enhance Innovation", "summary": "Madrigal Pharmaceuticals (MDGL) has secured three new patents for its drug resmetirom from the USPTO, strengthening its patent portfolio for long-term growth in the metabolic disease sector. While this bolsters its position for Rezdiffra, a treatment for MASH, the company's low G", "url": "https://www.gurufocus.com/news/8955300/madrigal-pharmaceuticals-mdgl-secures-new-patents-to-enhance-innovation", "source_name": "GuruFocus", "published_at": "2026-07-13T13:10:33", "published_display": "13 Jul 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Rezdiffra patents extend Madrigal\u2019s MASH IP into cirrhosis care", "summary": "Madrigal Pharmaceuticals announced the issuance of three new U.S. patents for its drug Rezdiffra (resmetirom). These patents strengthen its intellectual property portfolio for MASH treatment, specifically extending protection for F2/F3 MASH regimens until 2045 and 2042, and cover", "url": "https://www.stocktitan.net/news/MDGL/madrigal-pharmaceuticals-announces-three-new-resmetirom-patents-xdhdnv5vy54s.html", "source_name": "Stock Titan", "published_at": "2026-07-13T12:10:33", "published_display": "13 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal receives three new U.S. patents for resmetirom drug By Investing.com", "summary": "Madrigal Pharmaceuticals Inc. has secured three new U.S. patents for its drug resmetirom (Rezdiffra), extending protection for treating F2/F3 fibrosis stages until 2045 and 2042, and F4c cirrhosis until 2042. This patent expansion coincides with the company's increased market cap", "url": "https://ca.investing.com/news/stock-market-news/madrigal-receives-three-new-us-patents-for-resmetirom-drug-93CH-4731098", "source_name": "Investing.com Canada", "published_at": "2026-07-13T12:10:33", "published_display": "13 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio", "summary": "Madrigal Pharmaceuticals announced the issuance of three new U.S. resmetirom patents by the USPTO, bolstering its intellectual property portfolio for Rezdiffra (resmetirom). These patents include two reinforcing protection for F2/F3 MASH patients and one for the potential F4c cir", "url": "https://www.globenewswire.com/news-release/2026/07/13/3326143/0/en/madrigal-pharmaceuticals-announces-three-new-resmetirom-patents-strengthening-ip-portfolio.html", "source_name": "GlobeNewswire", "published_at": "2026-07-13T12:10:32", "published_display": "13 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal Pharmaceuticals, Inc. (MDGL) Investor Outlook: Unpacking a 26.46% Potential Upside", "summary": "Madrigal Pharmaceuticals, Inc. (MDGL) is a biotechnology company focused on metabolic dysfunction-associated steatohepatitis (MASH), with its flagship product Rezdiffra. Analysts are overwhelmingly bullish on MDGL, projecting a 26.46% potential upside from current levels, despite", "url": "https://www.directorstalkinterviews.com/madrigal-pharmaceuticals-inc-mdgl-investor-outlook-unpacking-a-26-46-potential-upside/4121256184", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:12:15", "published_display": "13 Jul 2026 09:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will siRNA MASH Candidate Nomination with Suzhou Ribo Change Madrigal Pharmaceuticals' (MDGL) Narrative?", "summary": "Madrigal Pharmaceuticals' partnership with Suzhou Ribo Life Science has achieved a significant milestone with the nomination of a first candidate drug for RNA-based liver disease therapeutics targeting MASH. This development could broaden Madrigal's pipeline beyond its current dr", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/will-sirna-mash-candidate-nomination-with-suzhou-ribo-change", "source_name": "Simply Wall Street", "published_at": "2026-07-12T15:40:07", "published_display": "12 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal Pharmaceuticals Slides 4.2% as Clear Negative Catalyst Remains Hard to Pin Down", "summary": "Madrigal Pharmaceuticals (MDGL) stock dropped 4.2% today, likely due to profit-taking after recent gains, rather than any clear negative company news. Despite the selloff, analysts maintain positive ratings and price targets, and the company reported continued pipeline progress a", "url": "https://www.quiverquant.com/news/Madrigal+Pharmaceuticals+Slides+4.2%25+as+Clear+Negative+Catalyst+Remains+Hard+to+Pin+Down", "source_name": "Quiver Quantitative", "published_at": "2026-07-10T21:20:00", "published_display": "10 Jul 2026 21:20", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Madrigal Pharmaceuticals (MDGL) Undervalued On Its New siRNA Milestone?", "summary": "Madrigal Pharmaceuticals (MDGL) is gaining attention after its partner reported a new siRNA candidate drug for liver diseases, including MASH. Despite strong past performance and recent index upgrades, the stock's valuation is debated, with a popular narrative suggesting it is 19", "url": "https://www.sahmcapital.com/news/content/is-madrigal-pharmaceuticals-mdgl-undervalued-on-its-new-sirna-milestone-2026-07-08", "source_name": "Sahm", "published_at": "2026-07-08T17:41:14", "published_display": "08 Jul 2026 17:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trading the Move, Not the Narrative: (MDGL) Edition", "summary": "This article analyzes Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL), highlighting strong sentiment across all horizons supporting an overweight bias. It outlines distinct institutional trading strategies, including position trading, momentum breakout, and risk hedging, based on AI", "url": "https://news.stocktradersdaily.com/news_release/43/Trading_the_Move,_Not_the_Narrative:_MDGL_Edition_070826053801_1783546681.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-08T17:38:00", "published_display": "08 Jul 2026 17:38", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA lowers its Price Target on Madrigal Pharmaceuticals, Inc. (MDGL)", "summary": "BofA has lowered its price target for Madrigal Pharmaceuticals, Inc. (MDGL) to $542 from $550, while maintaining a Neutral rating. The revision comes after discussions with key opinion leaders, leading to a reduced 2028 Rezdiffra revenue forecast. Separately, Madrigal and Ribo ac", "url": "https://www.insidermonkey.com/blog/bofa-lowers-its-price-target-on-madrigal-pharmaceuticals-inc-mdgl-1798283/", "source_name": "Insider Monkey", "published_at": "2026-07-08T15:20:00", "published_display": "08 Jul 2026 15:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Best Under-the-Radar Stocks to Invest In", "summary": "Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is featured as one of the best under-the-radar stocks, with 47 hedge funds holding positions. BofA recently lowered its price target on MDGL due to slightly reduced revenue forecasts for Rezdiffra, though the drug\u2019s launch in MASH has", "url": "https://www.insidermonkey.com/blog/5-best-under-the-radar-stocks-to-invest-in-1797323/3", "source_name": "Insider Monkey", "published_at": "2026-07-08T00:41:33", "published_display": "08 Jul 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)", "summary": "Madrigal Pharmaceuticals announced the grant of equity inducement awards to seven new non-executive employees on July 1, 2026, totaling options to purchase 604 shares and 2,952 time-based restricted stock units. These awards were approved by the independent Compensation Committee", "url": "https://finance.yahoo.com/healthcare/articles/madrigal-pharmaceuticals-announces-grants-inducement-200500872.html", "source_name": "Market source", "published_at": "2026-07-07T06:09:44", "published_display": "07 Jul 2026 06:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal gives seven new employees stock awards to join the company", "summary": "Madrigal Pharmaceuticals granted equity inducement awards to seven new non-executive employees on July 1, 2026. These awards include 604 stock options and 2,952 time-based Restricted Stock Units (RSUs), with an exercise price of $514.39 per share, as part of the company's 2025 In", "url": "https://www.stocktitan.net/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-mv5lbz51tb0y.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:10:15", "published_display": "06 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Madrigal\u2019s New siRNA MASH Candidate Shift Madrigal Pharmaceuticals' (MDGL) Rezdiffra-Centric Narrative", "summary": "Madrigal Pharmaceuticals' investment narrative is largely centered on its drug Rezdiffra for MASH. The recent progression of its siRNA partnership with Suzhou Ribo Life Science into IND-enabling studies introduces a new RNA-based approach to its pipeline, diversifying its develop", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/will-madrigals-new-sirna-mash-candidate-shift-madrigal-pharm", "source_name": "Simply Wall Street", "published_at": "2026-07-04T04:40:15", "published_display": "04 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MDGL - Madrigal Pharmaceuticals Inc Latest SEC Filings", "summary": "This article provides a detailed financial snapshot of Madrigal Pharmaceuticals Inc. (MDGL), including its latest stock performance, key financial metrics, insider and institutional ownership data, and various valuation ratios. It covers aspects like market capitalization, sales,", "url": "https://finviz.com/stock?t=MDGL&ta=1&p=m&ty=lf&page=4", "source_name": "Finviz", "published_at": "2026-07-03T16:10:06", "published_display": "03 Jul 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Madrigal Pharmaceuticals, Inc. \u2013 NASDAQ:MDGL", "summary": "The article displays the enterprise value to EBITDA forward for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL). The content comes from TradingView, referencing financial data from ICE Data Services and FactSet, and SEC filings from Quartr.", "url": "https://www.tradingview.com/symbols/NASDAQ-MDGL/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T15:40:28", "published_display": "02 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal and Ribo start IND-enabling studies after MASH milestone", "summary": "Madrigal Pharmaceuticals and Suzhou Ribo Life Science have achieved a significant milestone in their siRNA partnership for liver disease, nominating a candidate drug for MASH (Metabolic Dysfunction-Associated Steatohepatitis). This triggers the immediate start of IND-enabling stu", "url": "https://www.stocktitan.net/news/MDGL/ribo-and-madrigal-reach-first-major-milestone-in-advancing-novel-si-supr0a4mxbab.html", "source_name": "Stock Titan", "published_at": "2026-07-02T01:14:44", "published_display": "02 Jul 2026 01:14", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH", "summary": "Suzhou Ribo Life Science Co., Ltd. (Ribo) and Madrigal Pharmaceuticals, Inc. (Madrigal) have achieved their first major milestone in their siRNA partnership for metabolic dysfunction-associated steatohepatitis (MASH) therapies. This success involves the nomination of a candidate ", "url": "https://www.prnewswire.com/news-releases/ribo-and-madrigal-reach-first-major-milestone-in-advancing-novel-sirna-therapies-for-mash-302816515.html", "source_name": "PR Newswire", "published_at": "2026-07-02T01:09:31", "published_display": "02 Jul 2026 01:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler reiterates Madrigal Pharmaceuticals stock rating at $900", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNMXlmbC1kdUVCeTVMT3RnYXl0bWQ5b1dMeU1UdDlVRzRIYTBMakRDTTlqZUoyLUlKdEdKa3daX2tVeU5ody12endyVTluVFZUTlVaUUdEcDJnSXFqX0xjWUxzR2NLUzhjaDl2YWJDSXBvLXFlS3lwVWY1bDBmR1RKUnBOeGNvakZGMzA5MW44WW9kR3NocUJ4cm0yY2hXMS1EamFTZ3VWcTNMdnpzMnpBck9KV2xVekVSWFFELVNQVVNMUFVEUXZoYg?oc=5", "source_name": "Investing.com", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal (MDGL) Baker Bros.-aligned directors receive RSU and option awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQcHFZc2xacTVScHA5bWQzOFV1YmJVRHJkdEhfejY1X05iWnd3RUNXUjJ3R1UySGlqV2lpbnFESVBTYnFnNERzbTR0a2cwTno0Mk0zbkZ2emgyT0dfLXUzdDdUVndUMUxLM3Y4Q2pCOUNnM1Fnczdvbzk5ZWdlQUxpQXMxa2dnVUduX3hfYmMta09kdTRRZVhmZDVzUF9DaUZETzdiSzFRaEdqenNDbVdaOFF4VkxTb3pIS0tTOGY2OA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNS2lkWEJMeFViVkdGWHNFcUI3QXRNbExfMnNqUG1EUlB2UmpSam9FZ18xV05oYXh5MExObnM2MTh0OGttRlRYUDlBeHVKZzhEUEpBbWY1X3R0QXJCbjhmcVZha1QtS0FTcmJqdFNhOGFMd1dWbVBKV0JzbnZnLVNLR3BxM2lDWEE2S3ZQVDZUWUk?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal Pharmaceuticals (MDGL) slides as insider sale headlines hit and investors take profits", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPcnFpT2YxUmRrbzE1MTNYdGdzb2c3RTFQOUtfOGM0dDdOZDE1Wk43alJiUUpJSFlmTmJCdWdtRjl2TXZmaVBPRUxjUHpnQTVYcUI0aTVsZjhXbXRFOGE5NnRickpqVFZWUHRSTk5pcDgzdlNpMzJuNXFfajk1VFVkRFFHc0ctT0hUN1RnOEIwMkdINDJvZVNsODUwSlNzSnlYcWd1WkItMEdPZDB6c2dJc2JMTXhqdDBYZGp2QUt6LTE5czJ2a1RR?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal Pharmaceuticals Could Become The Next Vertex", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPLTl4cTFqMV9mRTgybThWU3VWbUJIVElYOXFzeGRqM195ck5USWoyNUZuZ2RSc3lYdmRSSm16UVJZcDB1aHZ0LVUzYXRaN0hKYTM0MnJ1cUtDNGp6MDdSQm5pa3ZVTWVRSVdEdk4wVTdrbDRCbThyQVdyVDJDUWNjeWRuX25ZWml0cUkwUEJNZGk3Mnp0MzFteGt3?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal (MDGL) CMO sells 1,042 shares in 10b5-1 trade, holds 10,033", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOR0E2V01YVEdqNE1aeDNKeE9jY0FmREZyQXRvajJtVm1WTDR3dEVXNkhFdzBBR0NQMVFlQ1c4a29ndC1hMkdYZTV1R2V2b29ESVZSc0ljdVdGd3N6WnVwNmw4OTBaa2hFU3ZxMlRqcXY0bjJnSGlMSlJCRTdrYnJ3eHRNSV9YTnJySDhLcFJmdF9JUjNzWVlRdHV6cnBmOF92Mmw0OXRwajZfMEFieU9JSFlydmtmOTkxamVoWTN3SQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MDGL (NASDAQ) insider files Form 144 reporting sale of 1,042 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPS0RpTXpvTGFZNEFSLWZaNks3VGtuMXBWT2NmZW1fQWlZOERkREhhVlNhVVNxMGtVc1BTeHh5RkZZQjA0UjYzLTgwNXpjZGMwRVcwYmszSzN5d2tBYnZwQVJabUdiVzRvblJZUWJ5cGY5Nm9WNFl0OW9zSUZ5YjJrekRGamYwUDlDelpvMG9nQndGb2daVUoyMm5MeDhGTmp6dHd3Y1Zhb0s?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Licenses ARO PNPLA3 To Madrigal To Expand MASH Options", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxOcm5lOTM5YUlicnViYUlERkxkMnZRTWl0d2F1ZWVWVTFOM0xRbjJsT0hDMVc2WnFwTTFJUW9DZWdWN1lOQkgxWFhBa1kwZHc3QzVVOTkxU09YMDV6cGIzOFA3YWlZLVk3ZjViQ2oySzlyRzE0S20zTWptY0k2Qy1UNEh5Z18xM3JmaW9hYzNVQS1janpYVFpQdWVqZjFzSTJlSkVNeE1xU191TE5UNkVHLWdsME56UFBYaDA1clZtTy1ldVl2TURPS0NscUVEQzduT2ZEOEYyNXpRZERzOGlpbkJldlJJVVNOVXp2Nm9CTG_SAfYBQVVfeXFMT1RaN2dkNE1nUlRxRTJ1ZlZpNldReG1hVHIydFJtdm1nVElWZXQ5cnp6TGxfeTJQb3VTMGRmbXJaOUczSnFnbEJObjdvNHRkR2NCV2ZWMThDLXo4RGVueVEyczVNeFk2ODZwSlRKWmFOekx0RkhpZG01RHFGdm5YSFZ2djF3NUF3S0VRZ0dCdE1rbU5tdHVaLTdJa0NjQVZuYWhQYmpHUml5cVc3MV95c0RHWmM1bHpZVUczalNELURDeWRfWFVlZ0ZsMFlocVhxZ0xOR0FhT1BtS3pVazltcFE3YWJZQ3lfZlVzYnZmWnVDa3Bzamt3?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Strong Q1 2026 Earnings And Rezdiffra Sales Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPN0F3S1FFWEMzdkYzZGtDWlpBczJ1VVJTa0NlZi1jaF8zQVRuenB5eHQyVl9oc1cyZjVQUVNEblQyaEFyQXN2UEtrSWpjZjFrMWRINy02Z09xclRzYlNxVmlYdTMwRFdZQm0zeFJ6S3Z1UXZvVllxbktDZVV0VmhzWThGMmFheGN6eDBvXzJqVmowRm9NbmVlb0hzckNTSWZqYk5xLWp4ampxNWstYVE?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal Pharmaceuticals (MDGL) Quarterly Loss Of US$94 Million Tests Bullish Margin Turnaround Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal Expands MASH Franchise With Precision RNAi License For ARO PNPLA3", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxPVm5sbmtma2JMYXFoWmlpdUdmVVB0X3NSM2tRQThrVUVDSldrZTBpNGNwQTJQMEVOaGFZdzVnM0RjY2xmM1hnYWZISVdDUEFzV1c3c2FxZ0JrbzE5OUZaRUxpczZ1NmxMUVI0cVo1cUhvazN2ODBVb00tbkp3amlucDRIb09DLUdiZHJXM0E1dkgtMnpNTWFWNmpOYVZGMFFmV05leTlFN0wzZko0blZhOXA3U0l4NGZmWDFDMXZYVGlFdDVCNU5ZcmNjb2JPOHBpLTlPMkxtdl9iX3BIWEhYNFJpa0kyNkNZbW9hclNn0gHzAUFVX3lxTE8xZ01UT1lhUnZDbk54aDBXVVRaempSSW5mdW1EN1F1VTM2UTNMUW9HNi0tbFkyMVp0VzdrSU9rY2tNSDdieVFOUE45RUV0VDJrZW1YQWsxNzU3RlRxWEVwa0xjZ3YtcEwyeWhFV0hSWDd3U0tQT1pCZHVDdFBLVHY1OG1nTGhueG1xcGVuWmRTVEM5MFB6ZGVFaXZPQ1l6OGdmTlBUN1VUWVcyS3luN1lvaEdtWkJ4TEZyM0pReXotWlFhSGlYNElnQ1k0VE9NMUNFU0QyR0xVanFSdTlPN1RoMFJqOVdUazA5SXg1bnlHOE13OA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNbUJ1ejhtaERNTHdac2hPVDRwNDV3cHoybE5pSUVodS1KdTBSMW1fZGtpd2ViUFdlNWNpdlMxR05KTHZnX3VEY3A1Rm1qNnQ0c1BvY19LVF9lMGlpN3FuQ2I1S0RtOTNyaFlMemRJOVJqdG1YaHJQRzZfLTRpczZQNlhxVDNVcmNuZmZxcEJMYXg3dHJJc2dqcnNWS1ZLNzQ?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess Madrigal Pharmaceuticals (MDGL) After Its Strong Five Year Share Price Gain", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal (MDGL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNdU04RUpwUmxTWnFNOEFLejNVSThrY1dkSm9lQlV4NV9XRHR0TVAxZU9yeUV1djVRb3ZnQWcwVG96cXVObnBOZ2NEbHJQTktVTHRZallKR21KNGxYTWQ1RGhJUWc4WVp1dDAzUDJSdk9wb2p1c2gyb3RESVNrRVk2bzVKWERHRkRGaWZ0S01CS19rYXpiREdkWFdsTWNTMHpKanM0?oc=5", "source_name": "Market source", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal Pharmaceuticals: Boom Or Bust In MASH? Regretfully, I'm Bearish (NASDAQ:MDGL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNcmdvWXEzS25pUzRXQUp3Vk9uTDh0b3B6Y1psZXN6UlczU0k2NDFRSTFMa3NoOTMwUTZzQURfckFqX2tLOGd4VUREQ291ejlqOHNNRzBBOTk5aHhpQzY5MW9Xc0ZqZkVMVVNjbElwZkZHMjJVQm1MMkJpRnV4dW1LRW1jMkQtSXBBS3BYNlRjRGJoTi1oZ0x4U3VXelBuOVpQODltN2xxS0NhaVRfZ1E?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is It Too Late To Consider Madrigal Pharmaceuticals (MDGL) After Recent Share Price Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOZEdKSU5aMFdqOTJvMDgySFV6UUJ2NzJiTXRTaHJ3ZmRJZTJ1Zzg3OHhYTkk5alZLT1pZVGg1emRDSGhvSFZEbFZEMl8zY1plOWFfeElMcV95QUkzZTNaNm96aVE3QzZhS1dKWlhYWmxDaERDdG5Ib0taTU1xRVVmcklBWEFhMHp6S0UyN1BLSkMyVGp5SVo4Ymh1QjcwbW9mWXpTQkdXLXJwdE0?oc=5", "source_name": "Market source", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Madrigal Pharmaceuticals (MDGL) Pricing Look Interesting After Long Term Share Price Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxPNlJKQVJxWTAxWEtPQ21CblJQY2ZoSnJ6MDRvazYwWlBBV0xLNzR5cWxJeDAyaDdOOHpEYVlCOFd5WHc1VWVhSnZNU0c2V2d6dHdDV2RDZDAxa2F4bFdLbkswOXEwOG8xdlg5Rml3bW9FeFp5eGpVY29KZExLcHd6TDlZSUczQzFtTG5KLWJpeS1iZw?oc=5", "source_name": "Market source", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes Madrigal Pharma (MDGL) One of the Shorted Biotech Stocks to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxQeWxVdjdZTXVZMVc2Y1Q5TW50amFwUlNIRG1DaTJEbS1RM2g3TXlQS1VEckUyMVVGbTktRFRyTDZoaGZSa29qSU9zdUVLOV8tOUFUX2dhUlYyUElUZm15bWNES1VJX1dpVDQwNkhSRk10dUR4aTAwTU1TbThwdFJwNXJB?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal learns its MASH drug Rezdiffra must share U.S. market, then gets Europe all to itself", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNQTJDN3pMbkdWQjdLeWtuTUdSUkFnYlp6SU83bEowa2JxeFVXZjN0M0ZOakVIMzdRWnEwY3RNb1NoQnRGaEFmWnl5emFONF84b2JUbmxXcHc1RjZlOTZnV0xsUThHS093RHNCVlpjOFpYbnRhTzRsckNHUXp6R1ZpZFNUampSNTdkUW1RYnU2ZTJSUkRKTmlyd0NJMEpTc0NoVE5DckxLcTBhaGs?oc=5", "source_name": "The Business Journals", "published_at": "2025-08-20T07:00:00+00:00", "published_display": "20 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-13T07:00:00+00:00", "published_display": "13 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Dow, S&P 500, Nasdaq Futures Rise After Trump\u2019s 10-Day Iran Pause: Why META, DJT, U, KOD, MDGL Are Trending After-Hours", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOZFFaTFpONXJlMV9wR2hQSU5mRTU3S3FQWjYwVmxSNFppcFpmQ0djM2JrQ1RzY09BTEl6MllqS2dFVGdoX2xvSkt4SWZieVFNLUtiVXJxN1ByeFVWRlJVZ2FZaU01S0UzNmdpTXMyejM3MGxZeDFTRnNqRlVYVjBFVVUxVWJqZTJOVF9SWFJWU0ctWGZzY0Fvb3ZTT2trWWxhcFJkUnpQb1hoVEFtMnd2RW1mVUNtbFJZTmZWNGZCcVIxWjdtUUE?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-19T10:24:50+00:00", "published_display": "19 Jul 2026 10:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citizens JMP Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Cuts Target Price to $739", "summary": "Citizens JMP has reiterated its Buy rating on Madrigal Pharmaceuticals (MDGL.US) but has reduced its target price to $739. The adjustment in the target price suggests a revised outlook on the company's valuation while maintaining a positive sentiment on its stock performance pote", "url": "https://www.moomoo.com/news/post/73137328/citizens-jmp-maintains-madrigal-pharmaceuticals-mdglus-with-buy-rating-cuts", "source_name": "Moomoo", "published_at": "2026-07-17T20:40:57", "published_display": "17 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026", "summary": "Madrigal Pharmaceuticals announced it will release its second-quarter 2026 financial results on July 30, 2026, before the U.S. financial markets open. Following the release, the company will host a live webcast at 8 a.m. Eastern Time to discuss its financial and operating results", "url": "https://www.globenewswire.com/news-release/2026/07/16/3328398/0/en/madrigal-pharmaceuticals-to-release-second-quarter-2026-financial-results-and-host-webcast-on-july-30-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-17T08:40:14", "published_display": "17 Jul 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Madrigal Pharmaceuticals (MDGL) Fully Valued Ahead Of Its July 30 Earnings?", "summary": "Madrigal Pharmaceuticals (MDGL) is approaching its Q2 2026 earnings release on July 30, with a current market value of US$12.7 billion. Despite recent share price momentum and a 5-year return of roughly 6x, the company is still considered 19.6% undervalued, with a fair value esti", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/is-madrigal-pharmaceuticals-mdgl-fully-valued-ahead-of-its-j/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-17T04:11:56", "published_display": "17 Jul 2026 04:11", "sentiment": "positive", "sentiment_pct": 68, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal management to discuss Q2 results at 8 a.m. Eastern July 30", "summary": "Madrigal Pharmaceuticals (Nasdaq: MDGL) announced it will release its second-quarter 2026 financial results on Thursday, July 30, 2026, before U.S. markets open. Management will host a live webcast at 8:00 a.m. Eastern time to review the results, with a replay available approxima", "url": "https://www.stocktitan.net/news/MDGL/madrigal-pharmaceuticals-to-release-second-quarter-2026-financial-xuxzpv0t0mcs.html", "source_name": "Stock Titan", "published_at": "2026-07-16T12:10:41", "published_display": "16 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biogen (BIIB) and Cadrenal Therapeutics, Inc. (CVKD)", "summary": "This article highlights bullish analyst ratings for three healthcare companies: Madrigal Pharmaceuticals (MDGL), Biogen (BIIB), and Cadrenal Therapeutics, Inc. (CVKD). Analysts from Truist Financial, Goldman Sachs, and Noble Financial reiterated Buy ratings, providing price targe", "url": "https://www.theglobeandmail.com/investing/markets/stocks/BIIB/pressreleases/3296321/analysts-offer-insights-on-healthcare-companies-madrigal-pharmaceuticals-mdgl-biogen-biib-and-cadrenal-therapeutics-inc-cvkd/", "source_name": "The Globe and Mail", "published_at": "2026-07-15T12:41:49", "published_display": "15 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal Pharmaceuticals' Three New Patents Support Patent Extension Into 2045, Truist Says", "summary": "Truist Securities has reiterated its Buy rating on Madrigal Pharmaceuticals (MDGL) after the company secured three new patents for its drug resmetirom. These patents are expected to extend the drug's exclusivity until 2045, enhancing its market position and providing long-term va", "url": "https://www.moomoo.com/news/post/72876322/madrigal-pharmaceuticals-three-new-patents-support-patent-extension-into-2045?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T22:42:19", "published_display": "13 Jul 2026 22:42", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal receives three new U.S. patents for resmetirom drug", "summary": "Madrigal Pharmaceuticals Inc. has been granted three new U.S. patents for its drug resmetirom, marketed as Rezdiffra, which treats metabolic dysfunction-associated steatohepatitis (MASH). These patents cover treatment for F2/F3 fibrosis stages and well-compensated cirrhosis, exte", "url": "https://www.investing.com/news/company-news/madrigal-receives-three-new-us-patents-for-resmetirom-drug-93CH-4788415", "source_name": "Investing.com", "published_at": "2026-07-13T15:12:15", "published_display": "13 Jul 2026 15:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal Pharmaceuticals Expands Rezdiffra Patent Protection With Three New Patents", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/madrigal-pharmaceuticals-expands-rezdiffra-patent-123800208.html", "source_name": "MT Newswires", "published_at": "2026-07-13T12:38:00+00:00", "published_display": "13 Jul 2026 12:38", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal Pharmaceuticals (MDGL) Secures New Patents to Enhance Innovation", "summary": "Madrigal Pharmaceuticals (MDGL) has secured three new patents for its drug resmetirom from the USPTO, strengthening its patent portfolio for long-term growth in the metabolic disease sector. While this bolsters its position for Rezdiffra, a treatment for MASH, the company's low G", "url": "https://www.gurufocus.com/news/8955300/madrigal-pharmaceuticals-mdgl-secures-new-patents-to-enhance-innovation", "source_name": "GuruFocus", "published_at": "2026-07-13T13:10:33", "published_display": "13 Jul 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Rezdiffra patents extend Madrigal\u2019s MASH IP into cirrhosis care", "summary": "Madrigal Pharmaceuticals announced the issuance of three new U.S. patents for its drug Rezdiffra (resmetirom). These patents strengthen its intellectual property portfolio for MASH treatment, specifically extending protection for F2/F3 MASH regimens until 2045 and 2042, and cover", "url": "https://www.stocktitan.net/news/MDGL/madrigal-pharmaceuticals-announces-three-new-resmetirom-patents-xdhdnv5vy54s.html", "source_name": "Stock Titan", "published_at": "2026-07-13T12:10:33", "published_display": "13 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal receives three new U.S. patents for resmetirom drug By Investing.com", "summary": "Madrigal Pharmaceuticals Inc. has secured three new U.S. patents for its drug resmetirom (Rezdiffra), extending protection for treating F2/F3 fibrosis stages until 2045 and 2042, and F4c cirrhosis until 2042. This patent expansion coincides with the company's increased market cap", "url": "https://ca.investing.com/news/stock-market-news/madrigal-receives-three-new-us-patents-for-resmetirom-drug-93CH-4731098", "source_name": "Investing.com Canada", "published_at": "2026-07-13T12:10:33", "published_display": "13 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio", "summary": "Madrigal Pharmaceuticals announced the issuance of three new U.S. resmetirom patents by the USPTO, bolstering its intellectual property portfolio for Rezdiffra (resmetirom). These patents include two reinforcing protection for F2/F3 MASH patients and one for the potential F4c cir", "url": "https://www.globenewswire.com/news-release/2026/07/13/3326143/0/en/madrigal-pharmaceuticals-announces-three-new-resmetirom-patents-strengthening-ip-portfolio.html", "source_name": "GlobeNewswire", "published_at": "2026-07-13T12:10:32", "published_display": "13 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal Pharmaceuticals, Inc. (MDGL) Investor Outlook: Unpacking a 26.46% Potential Upside", "summary": "Madrigal Pharmaceuticals, Inc. (MDGL) is a biotechnology company focused on metabolic dysfunction-associated steatohepatitis (MASH), with its flagship product Rezdiffra. Analysts are overwhelmingly bullish on MDGL, projecting a 26.46% potential upside from current levels, despite", "url": "https://www.directorstalkinterviews.com/madrigal-pharmaceuticals-inc-mdgl-investor-outlook-unpacking-a-26-46-potential-upside/4121256184", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:12:15", "published_display": "13 Jul 2026 09:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will siRNA MASH Candidate Nomination with Suzhou Ribo Change Madrigal Pharmaceuticals' (MDGL) Narrative?", "summary": "Madrigal Pharmaceuticals' partnership with Suzhou Ribo Life Science has achieved a significant milestone with the nomination of a first candidate drug for RNA-based liver disease therapeutics targeting MASH. This development could broaden Madrigal's pipeline beyond its current dr", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/will-sirna-mash-candidate-nomination-with-suzhou-ribo-change", "source_name": "Simply Wall Street", "published_at": "2026-07-12T15:40:07", "published_display": "12 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal Pharmaceuticals Slides 4.2% as Clear Negative Catalyst Remains Hard to Pin Down", "summary": "Madrigal Pharmaceuticals (MDGL) stock dropped 4.2% today, likely due to profit-taking after recent gains, rather than any clear negative company news. Despite the selloff, analysts maintain positive ratings and price targets, and the company reported continued pipeline progress a", "url": "https://www.quiverquant.com/news/Madrigal+Pharmaceuticals+Slides+4.2%25+as+Clear+Negative+Catalyst+Remains+Hard+to+Pin+Down", "source_name": "Quiver Quantitative", "published_at": "2026-07-10T21:20:00", "published_display": "10 Jul 2026 21:20", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Madrigal Pharmaceuticals (MDGL) Undervalued On Its New siRNA Milestone?", "summary": "Madrigal Pharmaceuticals (MDGL) is gaining attention after its partner reported a new siRNA candidate drug for liver diseases, including MASH. Despite strong past performance and recent index upgrades, the stock's valuation is debated, with a popular narrative suggesting it is 19", "url": "https://www.sahmcapital.com/news/content/is-madrigal-pharmaceuticals-mdgl-undervalued-on-its-new-sirna-milestone-2026-07-08", "source_name": "Sahm", "published_at": "2026-07-08T17:41:14", "published_display": "08 Jul 2026 17:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trading the Move, Not the Narrative: (MDGL) Edition", "summary": "This article analyzes Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL), highlighting strong sentiment across all horizons supporting an overweight bias. It outlines distinct institutional trading strategies, including position trading, momentum breakout, and risk hedging, based on AI", "url": "https://news.stocktradersdaily.com/news_release/43/Trading_the_Move,_Not_the_Narrative:_MDGL_Edition_070826053801_1783546681.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-08T17:38:00", "published_display": "08 Jul 2026 17:38", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA lowers its Price Target on Madrigal Pharmaceuticals, Inc. (MDGL)", "summary": "BofA has lowered its price target for Madrigal Pharmaceuticals, Inc. (MDGL) to $542 from $550, while maintaining a Neutral rating. The revision comes after discussions with key opinion leaders, leading to a reduced 2028 Rezdiffra revenue forecast. Separately, Madrigal and Ribo ac", "url": "https://www.insidermonkey.com/blog/bofa-lowers-its-price-target-on-madrigal-pharmaceuticals-inc-mdgl-1798283/", "source_name": "Insider Monkey", "published_at": "2026-07-08T15:20:00", "published_display": "08 Jul 2026 15:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Best Under-the-Radar Stocks to Invest In", "summary": "Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is featured as one of the best under-the-radar stocks, with 47 hedge funds holding positions. BofA recently lowered its price target on MDGL due to slightly reduced revenue forecasts for Rezdiffra, though the drug\u2019s launch in MASH has", "url": "https://www.insidermonkey.com/blog/5-best-under-the-radar-stocks-to-invest-in-1797323/3", "source_name": "Insider Monkey", "published_at": "2026-07-08T00:41:33", "published_display": "08 Jul 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)", "summary": "Madrigal Pharmaceuticals announced the grant of equity inducement awards to seven new non-executive employees on July 1, 2026, totaling options to purchase 604 shares and 2,952 time-based restricted stock units. These awards were approved by the independent Compensation Committee", "url": "https://finance.yahoo.com/healthcare/articles/madrigal-pharmaceuticals-announces-grants-inducement-200500872.html", "source_name": "Market source", "published_at": "2026-07-07T06:09:44", "published_display": "07 Jul 2026 06:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal gives seven new employees stock awards to join the company", "summary": "Madrigal Pharmaceuticals granted equity inducement awards to seven new non-executive employees on July 1, 2026. These awards include 604 stock options and 2,952 time-based Restricted Stock Units (RSUs), with an exercise price of $514.39 per share, as part of the company's 2025 In", "url": "https://www.stocktitan.net/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-mv5lbz51tb0y.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:10:15", "published_display": "06 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Madrigal\u2019s New siRNA MASH Candidate Shift Madrigal Pharmaceuticals' (MDGL) Rezdiffra-Centric Narrative", "summary": "Madrigal Pharmaceuticals' investment narrative is largely centered on its drug Rezdiffra for MASH. The recent progression of its siRNA partnership with Suzhou Ribo Life Science into IND-enabling studies introduces a new RNA-based approach to its pipeline, diversifying its develop", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/will-madrigals-new-sirna-mash-candidate-shift-madrigal-pharm", "source_name": "Simply Wall Street", "published_at": "2026-07-04T04:40:15", "published_display": "04 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MDGL - Madrigal Pharmaceuticals Inc Latest SEC Filings", "summary": "This article provides a detailed financial snapshot of Madrigal Pharmaceuticals Inc. (MDGL), including its latest stock performance, key financial metrics, insider and institutional ownership data, and various valuation ratios. It covers aspects like market capitalization, sales,", "url": "https://finviz.com/stock?t=MDGL&ta=1&p=m&ty=lf&page=4", "source_name": "Finviz", "published_at": "2026-07-03T16:10:06", "published_display": "03 Jul 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Madrigal Pharmaceuticals, Inc. \u2013 NASDAQ:MDGL", "summary": "The article displays the enterprise value to EBITDA forward for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL). The content comes from TradingView, referencing financial data from ICE Data Services and FactSet, and SEC filings from Quartr.", "url": "https://www.tradingview.com/symbols/NASDAQ-MDGL/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T15:40:28", "published_display": "02 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal and Ribo start IND-enabling studies after MASH milestone", "summary": "Madrigal Pharmaceuticals and Suzhou Ribo Life Science have achieved a significant milestone in their siRNA partnership for liver disease, nominating a candidate drug for MASH (Metabolic Dysfunction-Associated Steatohepatitis). This triggers the immediate start of IND-enabling stu", "url": "https://www.stocktitan.net/news/MDGL/ribo-and-madrigal-reach-first-major-milestone-in-advancing-novel-si-supr0a4mxbab.html", "source_name": "Stock Titan", "published_at": "2026-07-02T01:14:44", "published_display": "02 Jul 2026 01:14", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH", "summary": "Suzhou Ribo Life Science Co., Ltd. (Ribo) and Madrigal Pharmaceuticals, Inc. (Madrigal) have achieved their first major milestone in their siRNA partnership for metabolic dysfunction-associated steatohepatitis (MASH) therapies. This success involves the nomination of a candidate ", "url": "https://www.prnewswire.com/news-releases/ribo-and-madrigal-reach-first-major-milestone-in-advancing-novel-sirna-therapies-for-mash-302816515.html", "source_name": "PR Newswire", "published_at": "2026-07-02T01:09:31", "published_display": "02 Jul 2026 01:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler reiterates Madrigal Pharmaceuticals stock rating at $900", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNMXlmbC1kdUVCeTVMT3RnYXl0bWQ5b1dMeU1UdDlVRzRIYTBMakRDTTlqZUoyLUlKdEdKa3daX2tVeU5ody12endyVTluVFZUTlVaUUdEcDJnSXFqX0xjWUxzR2NLUzhjaDl2YWJDSXBvLXFlS3lwVWY1bDBmR1RKUnBOeGNvakZGMzA5MW44WW9kR3NocUJ4cm0yY2hXMS1EamFTZ3VWcTNMdnpzMnpBck9KV2xVekVSWFFELVNQVVNMUFVEUXZoYg?oc=5", "source_name": "Investing.com", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal (MDGL) Baker Bros.-aligned directors receive RSU and option awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQcHFZc2xacTVScHA5bWQzOFV1YmJVRHJkdEhfejY1X05iWnd3RUNXUjJ3R1UySGlqV2lpbnFESVBTYnFnNERzbTR0a2cwTno0Mk0zbkZ2emgyT0dfLXUzdDdUVndUMUxLM3Y4Q2pCOUNnM1Fnczdvbzk5ZWdlQUxpQXMxa2dnVUduX3hfYmMta09kdTRRZVhmZDVzUF9DaUZETzdiSzFRaEdqenNDbVdaOFF4VkxTb3pIS0tTOGY2OA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNS2lkWEJMeFViVkdGWHNFcUI3QXRNbExfMnNqUG1EUlB2UmpSam9FZ18xV05oYXh5MExObnM2MTh0OGttRlRYUDlBeHVKZzhEUEpBbWY1X3R0QXJCbjhmcVZha1QtS0FTcmJqdFNhOGFMd1dWbVBKV0JzbnZnLVNLR3BxM2lDWEE2S3ZQVDZUWUk?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal Pharmaceuticals (MDGL) slides as insider sale headlines hit and investors take profits", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPcnFpT2YxUmRrbzE1MTNYdGdzb2c3RTFQOUtfOGM0dDdOZDE1Wk43alJiUUpJSFlmTmJCdWdtRjl2TXZmaVBPRUxjUHpnQTVYcUI0aTVsZjhXbXRFOGE5NnRickpqVFZWUHRSTk5pcDgzdlNpMzJuNXFfajk1VFVkRFFHc0ctT0hUN1RnOEIwMkdINDJvZVNsODUwSlNzSnlYcWd1WkItMEdPZDB6c2dJc2JMTXhqdDBYZGp2QUt6LTE5czJ2a1RR?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal Pharmaceuticals Could Become The Next Vertex", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPLTl4cTFqMV9mRTgybThWU3VWbUJIVElYOXFzeGRqM195ck5USWoyNUZuZ2RSc3lYdmRSSm16UVJZcDB1aHZ0LVUzYXRaN0hKYTM0MnJ1cUtDNGp6MDdSQm5pa3ZVTWVRSVdEdk4wVTdrbDRCbThyQVdyVDJDUWNjeWRuX25ZWml0cUkwUEJNZGk3Mnp0MzFteGt3?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal (MDGL) CMO sells 1,042 shares in 10b5-1 trade, holds 10,033", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOR0E2V01YVEdqNE1aeDNKeE9jY0FmREZyQXRvajJtVm1WTDR3dEVXNkhFdzBBR0NQMVFlQ1c4a29ndC1hMkdYZTV1R2V2b29ESVZSc0ljdVdGd3N6WnVwNmw4OTBaa2hFU3ZxMlRqcXY0bjJnSGlMSlJCRTdrYnJ3eHRNSV9YTnJySDhLcFJmdF9JUjNzWVlRdHV6cnBmOF92Mmw0OXRwajZfMEFieU9JSFlydmtmOTkxamVoWTN3SQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MDGL (NASDAQ) insider files Form 144 reporting sale of 1,042 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPS0RpTXpvTGFZNEFSLWZaNks3VGtuMXBWT2NmZW1fQWlZOERkREhhVlNhVVNxMGtVc1BTeHh5RkZZQjA0UjYzLTgwNXpjZGMwRVcwYmszSzN5d2tBYnZwQVJabUdiVzRvblJZUWJ5cGY5Nm9WNFl0OW9zSUZ5YjJrekRGamYwUDlDelpvMG9nQndGb2daVUoyMm5MeDhGTmp6dHd3Y1Zhb0s?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arrowhead Licenses ARO PNPLA3 To Madrigal To Expand MASH Options", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxOcm5lOTM5YUlicnViYUlERkxkMnZRTWl0d2F1ZWVWVTFOM0xRbjJsT0hDMVc2WnFwTTFJUW9DZWdWN1lOQkgxWFhBa1kwZHc3QzVVOTkxU09YMDV6cGIzOFA3YWlZLVk3ZjViQ2oySzlyRzE0S20zTWptY0k2Qy1UNEh5Z18xM3JmaW9hYzNVQS1janpYVFpQdWVqZjFzSTJlSkVNeE1xU191TE5UNkVHLWdsME56UFBYaDA1clZtTy1ldVl2TURPS0NscUVEQzduT2ZEOEYyNXpRZERzOGlpbkJldlJJVVNOVXp2Nm9CTG_SAfYBQVVfeXFMT1RaN2dkNE1nUlRxRTJ1ZlZpNldReG1hVHIydFJtdm1nVElWZXQ5cnp6TGxfeTJQb3VTMGRmbXJaOUczSnFnbEJObjdvNHRkR2NCV2ZWMThDLXo4RGVueVEyczVNeFk2ODZwSlRKWmFOekx0RkhpZG01RHFGdm5YSFZ2djF3NUF3S0VRZ0dCdE1rbU5tdHVaLTdJa0NjQVZuYWhQYmpHUml5cVc3MV95c0RHWmM1bHpZVUczalNELURDeWRfWFVlZ0ZsMFlocVhxZ0xOR0FhT1BtS3pVazltcFE3YWJZQ3lfZlVzYnZmWnVDa3Bzamt3?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Strong Q1 2026 Earnings And Rezdiffra Sales Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPN0F3S1FFWEMzdkYzZGtDWlpBczJ1VVJTa0NlZi1jaF8zQVRuenB5eHQyVl9oc1cyZjVQUVNEblQyaEFyQXN2UEtrSWpjZjFrMWRINy02Z09xclRzYlNxVmlYdTMwRFdZQm0zeFJ6S3Z1UXZvVllxbktDZVV0VmhzWThGMmFheGN6eDBvXzJqVmowRm9NbmVlb0hzckNTSWZqYk5xLWp4ampxNWstYVE?oc=5", "source_name": "Market source", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal Pharmaceuticals (MDGL) Quarterly Loss Of US$94 Million Tests Bullish Margin Turnaround Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal Expands MASH Franchise With Precision RNAi License For ARO PNPLA3", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNbUJ1ejhtaERNTHdac2hPVDRwNDV3cHoybE5pSUVodS1KdTBSMW1fZGtpd2ViUFdlNWNpdlMxR05KTHZnX3VEY3A1Rm1qNnQ0c1BvY19LVF9lMGlpN3FuQ2I1S0RtOTNyaFlMemRJOVJqdG1YaHJQRzZfLTRpczZQNlhxVDNVcmNuZmZxcEJMYXg3dHJJc2dqcnNWS1ZLNzQ?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess Madrigal Pharmaceuticals (MDGL) After Its Strong Five Year Share Price Gain", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal (MDGL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNdU04RUpwUmxTWnFNOEFLejNVSThrY1dkSm9lQlV4NV9XRHR0TVAxZU9yeUV1djVRb3ZnQWcwVG96cXVObnBOZ2NEbHJQTktVTHRZallKR21KNGxYTWQ1RGhJUWc4WVp1dDAzUDJSdk9wb2p1c2gyb3RESVNrRVk2bzVKWERHRkRGaWZ0S01CS19rYXpiREdkWFdsTWNTMHpKanM0?oc=5", "source_name": "Market source", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal Pharmaceuticals: Boom Or Bust In MASH? Regretfully, I'm Bearish (NASDAQ:MDGL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNcmdvWXEzS25pUzRXQUp3Vk9uTDh0b3B6Y1psZXN6UlczU0k2NDFRSTFMa3NoOTMwUTZzQURfckFqX2tLOGd4VUREQ291ejlqOHNNRzBBOTk5aHhpQzY5MW9Xc0ZqZkVMVVNjbElwZkZHMjJVQm1MMkJpRnV4dW1LRW1jMkQtSXBBS3BYNlRjRGJoTi1oZ0x4U3VXelBuOVpQODltN2xxS0NhaVRfZ1E?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Madrigal Pharmaceuticals (MDGL) After Recent Share Price Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOZEdKSU5aMFdqOTJvMDgySFV6UUJ2NzJiTXRTaHJ3ZmRJZTJ1Zzg3OHhYTkk5alZLT1pZVGg1emRDSGhvSFZEbFZEMl8zY1plOWFfeElMcV95QUkzZTNaNm96aVE3QzZhS1dKWlhYWmxDaERDdG5Ib0taTU1xRVVmcklBWEFhMHp6S0UyN1BLSkMyVGp5SVo4Ymh1QjcwbW9mWXpTQkdXLXJwdE0?oc=5", "source_name": "Market source", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Madrigal Pharmaceuticals (MDGL) Pricing Look Interesting After Long Term Share Price Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxPNlJKQVJxWTAxWEtPQ21CblJQY2ZoSnJ6MDRvazYwWlBBV0xLNzR5cWxJeDAyaDdOOHpEYVlCOFd5WHc1VWVhSnZNU0c2V2d6dHdDV2RDZDAxa2F4bFdLbkswOXEwOG8xdlg5Rml3bW9FeFp5eGpVY29KZExLcHd6TDlZSUczQzFtTG5KLWJpeS1iZw?oc=5", "source_name": "Market source", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes Madrigal Pharma (MDGL) One of the Shorted Biotech Stocks to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxQeWxVdjdZTXVZMVc2Y1Q5TW50amFwUlNIRG1DaTJEbS1RM2g3TXlQS1VEckUyMVVGbTktRFRyTDZoaGZSa29qSU9zdUVLOV8tOUFUX2dhUlYyUElUZm15bWNES1VJX1dpVDQwNkhSRk10dUR4aTAwTU1TbThwdFJwNXJB?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Madrigal learns its MASH drug Rezdiffra must share U.S. market, then gets Europe all to itself", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNQTJDN3pMbkdWQjdLeWtuTUdSUkFnYlp6SU83bEowa2JxeFVXZjN0M0ZOakVIMzdRWnEwY3RNb1NoQnRGaEFmWnl5emFONF84b2JUbmxXcHc1RjZlOTZnV0xsUThHS093RHNCVlpjOFpYbnRhTzRsckNHUXp6R1ZpZFNUampSNTdkUW1RYnU2ZTJSUkRKTmlyd0NJMEpTc0NoVE5DckxLcTBhaGs?oc=5", "source_name": "The Business Journals", "published_at": "2025-08-20T07:00:00+00:00", "published_display": "20 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-13T07:00:00+00:00", "published_display": "13 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 93, "total_relevant": 55, "sentiment_summary": {"positive": 26, "negative": 3, "neutral": 26, "score": 59, "total": 55, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 15.55, "count": 27}, {"event": "earnings", "label": "Earnings", "weight": 8.25, "count": 17}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "deals", "label": "Deals and strategy", "weight": 2.2, "count": 4}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}], "positive_events": 26, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 553.48, "latest_week": "2026-07-17", "one_week_move": 3.1, "four_week_move": 9.4, "twelve_week_move": 8.0, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.291072, "market_dynamics_buy_signal": false, "relative_strength": 3.505077, "fair_value_gap": 67.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 47.8626, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+3.1% over one week, +9.4% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 68, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 14}, {"label": "Stock Titan", "count": 7}, {"label": "simplywall.st", "count": 7}, {"label": "Simply Wall Street", "count": 3}, {"label": "Moomoo", "count": 2}, {"label": "GlobeNewswire", "count": 2}, {"label": "Investing.com", "count": 2}, {"label": "Quiver Quantitative", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 47}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 27}, {"label": "Earnings", "count": 17}, {"label": "Analyst action", "count": 5}, {"label": "Deals and strategy", "count": 4}, {"label": "Guidance", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "59/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "47", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+3.1% over one week, +9.4% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Dow, S&P 500, Nasdaq Futures Rise After Trump\u2019s 10-Day Iran Pause: Why META, DJT, U, KOD, MDGL Are Trending After-Hours"}], "updated_at": "2026-07-19T18:06:42.719235+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}